| pubmed-article:20549894 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20549894 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20549894 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:20549894 | lifeskim:mentions | umls-concept:C0001617 | lld:lifeskim |
| pubmed-article:20549894 | lifeskim:mentions | umls-concept:C0339143 | lld:lifeskim |
| pubmed-article:20549894 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20549894 | pubmed:dateCreated | 2010-6-16 | lld:pubmed |
| pubmed-article:20549894 | pubmed:abstractText | Graves' ophthalmopathy is a debilitating disease impairing the quality of life of affected individuals. The management of moderate-to-severe active Graves' ophthalmopathy is a major therapeutic challenge, and the treatment outcome is often unsatisfactory. We have carried out a retrospective study to assess the efficacy of combined orbital irradiation and systemic corticosteroids. Ten patients were included; all patients had received 20 Grays to the retrobulbar tissues in ten fractions, and oral or intravenous glucocorticoids. The main therapeutic outcome measures were the criteria of Donaldson and co-workers and a self-assessment evaluation. The quality of life outcome was also evaluated by the GO-QOL (Graves' ophthalmopathy quality of life) questionnaire. Seven patients (70%) demonstrated improvement in ocular parameters; the response was excellent in three cases, good in three cases and fair in one case. Three patients showed no response to the treatment. The self-assessment evaluation showed that 75% of patients were satisfied with the results of the treatment. Proptosis was the most responsive sign to radiation and steroids. A duration of the eye disease of more than 18 months was associated with less improvement and a higher failure of the treatment. Concerning the quality of life, the score for visual fonctionning was 882 +/- 18.2 after treatment, while the score for appearance was 63.3 +/- 23.3. In conclusion, a combination of orbital irradiation and systemic steroids is associated with 70% of favorable responses, but the quality of life is not restored in the same proportions and remains impaired after treatment. | lld:pubmed |
| pubmed-article:20549894 | pubmed:language | fre | lld:pubmed |
| pubmed-article:20549894 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20549894 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20549894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20549894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20549894 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20549894 | pubmed:issn | 0023-9852 | lld:pubmed |
| pubmed-article:20549894 | pubmed:author | pubmed-author:NasrElieE | lld:pubmed |
| pubmed-article:20549894 | pubmed:author | pubmed-author:JambartSelimS | lld:pubmed |
| pubmed-article:20549894 | pubmed:author | pubmed-author:AzouryFaresF | lld:pubmed |
| pubmed-article:20549894 | pubmed:author | pubmed-author:Nehme-NasrDol... | lld:pubmed |
| pubmed-article:20549894 | pubmed:author | pubmed-author:KhaterSherine... | lld:pubmed |
| pubmed-article:20549894 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20549894 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:20549894 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20549894 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20549894 | pubmed:pagination | 86-90 | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:meshHeading | pubmed-meshheading:20549894... | lld:pubmed |
| pubmed-article:20549894 | pubmed:articleTitle | [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy]. | lld:pubmed |
| pubmed-article:20549894 | pubmed:affiliation | Service de Radiothérapie, CHU Hôtel-Dieu de France, Beyrouth, Liban. nasre@inco.com.lb | lld:pubmed |
| pubmed-article:20549894 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20549894 | pubmed:publicationType | English Abstract | lld:pubmed |
